Clinical trials: Myasthenia Gravis (MG)
Refractory Myasthenia Gravis
A Pilot Trial of Rituxan in Refractory Myasthenia Gravis
Myasthenia gravis is a disease that happens because the immune system attacks the nervous system. The damage is caused by antibodies produced by B lymphocytes.
- Trial name
- NCT00619671
- Testing
- Rituximab (Rituxan)
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Vermont
Myasthenia Gravis, Generalized Myasthenia
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.
- Conditions
- Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG
- Trial name
- NCT06106672
- Testing
- CNP-106
- Where
- 17 sites in United States
- Volunteers
- 54 people
- Sponsor
- COUR Pharmaceutical Development Company, Inc.
Myasthenia Gravis, Generalized
Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
Efficacy and safety of amifampridine phosphate in improving the activities of daily living for patients with antibody positive MuSK myasthenia gravis.
- Trial name
- NCT03304054
- Testing
- Amifampridine Phosphate
- Where
- 2 sites in United States
- Volunteers
- 93 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Multiple Sclerosis, Myasthenia Gravis
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or…
- Trial name
- NCT06220201
- Testing
- CC-97540, Fludarabine, Cyclophosphamide
- Where
- 34 sites in United States, Belgium and 4 more
- Volunteers
- 120 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
System Lupus Erythematosus(SLE), Scleroderma
Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
A FIH, single arm, open-label, Investigator Initiated Trial (IIT) study to evaluate the safety and tolerability of EVM18001 in the treatment of active refractory autoimmune diseases (SLE, MG, and SSc), and determine the…
- Conditions
- System Lupus Erythematosus(SLE), Scleroderma, Myasthenia Gravis (MG)
- Trial name
- NCT07470151
- Testing
- EVM18001 Injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Myasthenia Gravis
Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis
The study is being done with patients with Myasthenia Gravis (MG), age 18-80 years, positive acetylcholine receptor antibody, receiving greater than 30mg of prednisone daily.
- Trial name
- SIMM (NCT01828294)
- Testing
- Subcutaneous immunoglobulins
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- St. Louis University
Myasthenia Gravis
The EXPLORE MG Registry for Myasthenia Gravis
The purpose of this study is to create a Yale University Department of Neurology Myasthenia Gravis (MG) registry that will be used for current and future research projects involving the study of Myasthenia Gravis.
- Trial name
- NCT03792659
- Testing
- Blood Sample Draw
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- Yale University
Myasthenia Gravis
Subcutaneous Immunoglobulin for Myasthenia Gravis
This is a prospective open-label, randomized, parallel arm clinical trial. The primary objective of the study is to evaluate the safety and efficacy of Cuvitru 20% subcutaneous immunoglobulin in patients with myasthenia gravis…
- Trial name
- MG_SCIG (NCT04728425)
- Testing
- subcutaneous immunoglobulin (SCIG), intravenous immunoglobulin + subcutaneous immunoglobulin (SCIG)
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Generalized Myasthenia Gravis
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).
- Trial name
- NCT05556096
- Testing
- ALXN1720
- Where
- 132 sites in United States, Argentina and 20 more
- Volunteers
- 260 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Generalized Myasthenia Gravis
Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)
This is an open label, single arm study, to evaluate safety, tolerability and preliminary efficacy of HN2301 in patients with Generalized Myasthenia Gravis.
- Trial name
- NCT07556120
- Testing
- HN2301 injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Shenzhen MagicRNA Biotechnology Co., Ltd
Myasthaenia Gravis
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor autoantibody -positive generalized myasthenia gravis.
- Trial name
- NCT06799247
- Testing
- Decartes-08
- Where
- 34 sites in United States, Canada and 6 more
- Volunteers
- 128 people
- Sponsor
- Cartesian Therapeutics
Myasthenia Gravis, MuSK MG
MuSK Myasthenia 1000 Study
The MuSK myasthenia gravis 1000 study seeks to collect saliva samples from 1000 subjects with laboratory confirmed diagnosis of MuSK myasthenia to identify genetic variations associated with MuSK MG.
- Conditions
- Myasthenia Gravis, MuSK MG, MuSK Myasthenia Gravis
- Trial name
- MuSK 1000 (NCT06259071)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- George Washington University
Myasthenia Gravis, MuSK, AChR Myasthenia Gravis
Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
Evaluate the long-term safety of amifampridine phosphate in patients with MuSK antibody positive and AChR antibody positive myasthenia gravis.
- Trial name
- NCT03579966
- Testing
- Amifampridine Phosphate
- Where
- 3 sites in United States, Italy
- Volunteers
- 63 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Generalized Myasthenia Gravis, MG - Myasthenia Gravis
An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis
The purpose of this open-label study is to investigate the efficacy, safety, and tolerability of a continuous regimen of efgartigimod compared with a cyclic regimen in participants with Generalized Myasthenia Gravis (gMG).
- Conditions
- Generalized Myasthenia Gravis, MG - Myasthenia Gravis, gMG
- Trial name
- ADAPT NXT (NCT04980495)
- Testing
- Efgartigimod IV
- Where
- 39 sites in United States, Austria and 9 more
- Volunteers
- 69 people
- Sponsor
- argenx
Myasthenia Gravis, Ocular, Gene Polymorphism
Association Study Between VDR Gene Polymorphisms and Risk and Features of MG in Han Chinese Population
The Vitamin D receptor gene (VDR) polymorphisms are the candidate genetic variants for susceptibility to autoimmune diseases. In the present study, the investigators aimed to assess the association between VDR polymorphisms and…
- Trial name
- NCT05380128
- Testing
- Genotype analysis for VDR rs1544410, rs2228570, rs731236, and rs7975232 polymorphisms
- Where
- China
- Volunteers
- 297 people, healthy volunteers welcome
- Sponsor
- Beijing Tongren Hospital
Myasthaenia Gravis
The Evaluation of Belimumab in Myasthenia Gravis (MG)
Study BEL115123 is a randomized, placebo-controlled, double-blind, multinational study of belimumab (10 mg/kg) to investigate the efficacy and safety of belimumab in subjects with MG.
- Trial name
- NCT01480596
- Testing
- Belimumab
- Where
- 25 sites in United States, Canada and 2 more
- Volunteers
- 40 people
- Sponsor
- GlaxoSmithKline
Myasthenia Gravis, Fatigue
Capturing Key MG-symptoms Using Smartphone Recordings.
This study will make use of a cross-sectional design of MG patients and non-MG participants to quantitatively assess key MG symptoms, and to explore the applicability of machine learning algorithms to their measurement.
- Trial name
- CAPTURE - MG (NCT06743490)
- Where
- 2 sites in Netherlands
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Myasthenia Gravis, Generalized
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
This is a Phase IIb study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis
- Trial name
- NCT04146051
- Testing
- Descartes-08
- Where
- 15 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Cartesian Therapeutics
Myasthenia Gravis
Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis
The purpose of this study is to determine whether Hizentra is a safe and effective treatment for people with myasthenia gravis (MG).
- Trial name
- NCT02100969
- Testing
- HIZENTRA ®
- Where
- 5 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- Mazen Dimachkie, MD
Myasthenia Gravis (MG)
Ripertamab for the Treatment of Myasthenia Gravis
The goal of this clinical trial is to learn if ripertamab works to treat myasthenia gravis. It will also learn about the safety of ripertamab.
- Trial name
- RIPERT-MG (NCT07372807)
- Testing
- ripertamab
- Volunteers
- 20 people
- Sponsor
- Zhongming Qiu